“BioPlus Expands HUGRO Global Strategy with New Pangyo HQ”

[Kim Saemi, Edaily Reporter] BioPlus Inc. has been officially selected as the final candidate to move into a dedicated site for industry-academia-research collaboration within the Pangyo 2nd Techno Valley High-Tech Industrial Complex. This marks a significant step forward in the company’s global ambitions, particularly centered on the patented next-generation bio-technology, HUGRO.

Bird’s-eye View of BioPlus’ New Pangyo Headquarters (Source: BioPlus)

With this selection, BioPlus plans to establish a new headquarters in Pangyo Innovalley and integrate its current Seoul office and R&D center in Songpa into a unified HUGRO R&D Center. More than a relocation, this marks a strategic pivot to position HUGRO as a global innovation powerhouse.

HUGRO is a high-performance bioactive material developed solely by BioPlus, protected under international patents. It is based on a proprietary growth factor peptide combination technology used in skin therapeutics. Designed for applications in raw materials for pharmaceuticals and cosmetic ingredients, HUGRO promotes skin regeneration, anti-aging, wrinkle improvement, and brightening, helping restore the skin’s natural functions. By optimizing the combination of key growth factors (EGF, FGF, TGF, VEGF, and PDGF) HUGRO overcomes the limitations of single peptides, positioning itself as a next-generation skincare solution.

The Pangyo relocation is not only about enhancing technological capabilities but also about establishing a strategic base for linking R&D with global commercialization. The BioPlus consortium, including academic partners such as the Hanyang University Industry-Academic Cooperation Foundation, aims to accelerate the development of convergent bio-health technologies based on biopolymers and stem cells.

Boin Jung, Head of Marketing Strategy at BioPlus, stated, “With HUGRO Peptides, we aim to set the global standard for K-bio materials,” and added, “The beginning of our Pangyo chapter will be the launchpad for becoming a leading premium bio company in the global market.”